This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Sotera Health Company (SHC) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Sotera Health (SHC) delivered earnings and revenue surprises of 11.76% and 3.42%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
DocGo Inc. (DCGO) Matches Q1 Earnings Estimates
by Zacks Equity Research
Motion Acquisition (DCGO) delivered earnings and revenue surprises of 0% and 3.63%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AMN Healthcare Services (AMN) Q1 Earnings Expected to Decline
by Zacks Equity Research
AMN Healthcare (AMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DocGo Inc. (DCGO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Motion Acquisition (DCGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DocGo Inc. (DCGO) Q4 Earnings Lag Estimates
by Zacks Equity Research
DocGo Inc. (DCGO) delivered earnings and revenue surprises of -53.85% and 1.93%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
DocGo Inc. (DCGO) Moves 6.8% Higher: Will This Strength Last?
by Zacks Equity Research
DocGo Inc. (DCGO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
DocGo Inc. (DCGO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
DocGo Inc. (DCGO) delivered earnings and revenue surprises of -166.67% and 4.89%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
DocGo Inc. (DCGO) Surges 5.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
DocGo Inc. (DCGO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Are Options Traders Betting on a Big Move in DocGo (DCGO) Stock?
by Zacks Equity Research
Investors need to pay close attention to DocGo (DCGO) stock based on the movements in the options market lately.
DocGo Inc. (DCGO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
DocGo Inc. (DCGO) delivered earnings and revenue surprises of -200% and 1.04%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
DocGo Inc. (DCGO) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
DocGo Inc. (DCGO) delivered earnings and revenue surprises of 120% and 4.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Motion Acquisition (DCGO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how DocGo Inc. (DCGO) and Shockwave Medical (SWAV) have performed compared to their sector so far this year.
Is Molina Healthcare (MOH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Molina (MOH) and DocGo Inc. (DCGO) have performed compared to their sector so far this year.
Wall Street Analysts Think DocGo Inc. (DCGO) Could Surge 27%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 26.8% upside potential for DocGo Inc. (DCGO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Can DocGo Inc. (DCGO) Climb 30% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for DocGo Inc. (DCGO) points to a 30% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Can DocGo Inc. (DCGO) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
DocGo Inc. (DCGO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Earnings Season Could Be Great for DocGo (DCGO)
by Zacks Equity Research
DocGo (DCGO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
3 Healthcare Stocks Poised to Surpass Earnings Estimates in Q1
by Debasmita Chatterjee
Improved patient volumes, a diversified healthcare portfolio and various technological advancements are likely to favor first-quarter results of ELAN, DCGO and OMIC.
Wall Street Analysts See a 92% Upside in DocGo Inc. (DCGO): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 91.8% upside potential for DocGo Inc. (DCGO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
DocGo and Post Holdings have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
DocGo and Post Holdings have been highlighted as Zacks Bull and Bear of the Day.
Bull Of The Day: DocGo (DCGO)
by Brian Bolan
It may still be very early, but this company could change the way we think of non-emergency healthcare
How Much Upside is Left in DocGo Inc. (DCGO)? Wall Street Analysts Think 105%
by Zacks Equity Research
The consensus price target hints at a 104.5% upside potential for DocGo Inc. (DCGO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Predict a 97% Upside in DocGo Inc. (DCGO): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for DocGo Inc. (DCGO) points to a 96.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Teladoc (TDOC) Falls 8.1% Despite Upbeat Revenue Guidance
by Zacks Equity Research
Teladoc Health (TDOC) expects revenues to rise to more than $4 billion in 2024.